# US 2008/0305046 A1 · Molecular imaging methods for diagnosis and evaluation of ocular and systemic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305046 A1
- Document ID: US20080305046A1
- Status: Published application
- Kind: A1
- Application number: 11/970,333
- Filed: 2008-01-07
- Published: 2008-12-11
- Earliest claimed: 2007-02-16
- Inventors: Ali Hafezi-Moghadam
- Web page: https://patentgrep.com/patent/US20080305046A1

## CPC

- A61B 3/1233: {for measuring blood flow, e.g. at the retina}
- A61B 3/1025: {for confocal scanning}
- A61B 3/1241: {specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography}
- A61B 5/14546: {for measuring analytes not otherwise provided for, e.g. ions, cytochromes}
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates generally to minimally-invasive, in vivo methods of detecting one or more ligands on an intraluminal surface of a blood vessel using microparticles coated with one or more ligand binding partners. More particularly, in certain embodiments, the invention relates to minimally-invasive, in vivo methods of detecting endothelial and leukocyte antigens that are predictive of diabetic retinopathy (DR) and/or other conditions using protein-conjugated microparticles detectable by a non-invasive detection system, for example, a scanning laser opthalmoscope. In other embodiments, the invention relates to targeted delivery of drugs or other substances to specific regions of an intraluminal surface of a blood vessel using drug-containing microparticles coated with one or more ligand binding partners.

## Claims

### Claim 1

A minimally invasive method for the in vivo detection of one or more ligands on an intraluminal surface of a blood vessel, the method comprising:
(a) administering microparticles to a subject, wherein the microparticles have an average diameter less than a diameter of a blood vessel of the subject in which the microparticles travel, and wherein the microparticles have a surface to which one or more substances are conjugated, wherein the one or more substances interact with one or more ligands on an intraluminal surface of the blood vessel thereby inhibiting movement of the microparticles through the blood vessel; and
(b) detecting one or more of the administered microparticles in the blood vessel using a non-invasive detection device.

### Claim 2 (depends on 1)

The method of claim 1, wherein the one or more substances conjugated to the surface of the microparticles bind to the one or more ligands on the intraluminal surface of the blood vessel.

### Claim 3 (depends on 1)

The method of claim 1, wherein the one or more ligands comprise one or more native ligands.

### Claim 4 (depends on 1)

The method of claim 1, wherein the one or more ligands comprise exogenous ligands.

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more substances conjugated to the surface of the microparticles are covalently bound to the surface of the microparticles.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the microparticles are fluorescent microparticles and the detection device is a scanning laser opthalmoscope.

### Claim 8 (depends on 1)

The method of claim 1, wherein the one or more ligands on the intraluminal surface comprise an endothelial surface antigen, a leukocyte surface antigen, or both.

### Claim 9 (depends on 1)

The method of claim 1, wherein the one or more ligands on the intraluminal surface comprise one or more members selected from the group consisting of a platelet antigen, a cell surface molecule, a micro-particle antigen, a protein, a lipid, a carbohydrate, a glycoprotein, a lipoprotein, a bacterial antigen, a viral antigen, a parasite antigen, and a cancer cell antigen.

### Claim 10 (depends on 1)

The method of claim 1, wherein the one or more ligands accumulate on the intraluminal surface of the blood vessel.

### Claim 11 (depends on 1)

The method of claim 1, comprising determining one or more parameters selected from the group consisting of a rolling parameter, a tethering parameter, and an adhesion parameter for one or more of the microparticles in the blood vessel, wherein the one or more parameters are indicative of the presence of one or more of the ligands on the intraluminal surface of the blood vessel.

### Claim 12 (depends on 11)

The method of claim 11, wherein the one or more ligands on the intraluminal surface comprise an endothelial surface antigen, a leukocyte surface antigen, or both.

### Claim 13 (depends on 11)

The method of claim 11, wherein the one or more parameters are indicative of inflammation in the blood vessel.

### Claim at position 14

-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, further comprising identifying a sub-clinical manifestation of diabetic retinopathy based at least in part on the one or more microparticles detected in step (b).

### Claim 17 (depends on 1)

The method of claim 1, further comprising identifying endothelial injury in a choroidal blood vessel based at least in part on the one or more microparticles detected in step (b).

### Claim 18 (depends on 17)

The method of claim 17, comprising identifying endothelial injury in choriocapillaris during endotoxin-induced uveitis.

### Claim at position 18

-20. (canceled)

### Claim 21 (depends on 1)

The method of claim 1, further comprising identifying a change in permeability of a blood vessel based at least in part on the one or more microparticles detected in step (b).

### Claim 22 (depends on 1)

The method of claim 1, further comprising diagnosing a medical condition.

### Claim 23 (depends on 22)

The method of claim 22, wherein the medical condition comprises a member selected from the group consisting of diabetic retinopathy, atheroscloerosis, an autoimmune disease, Alzheimer's Disease, glaucoma, and macular degeneration.

### Claim 24

(canceled)

### Claim 25 (depends on 22)

The method of claim 22, wherein the medical condition comprises a member selected from the group consisting of a neuronal disease, a neuro-degenerative disease, a thrombosis-related disease, a hemostasis-related disease, a metabolic disease, a vascular congenital disease, a congenital disease, an endocrine disease, a trauma induced condition, a hematological disease, an oncological disease, a renal disease, a urological disease, a hepatological disease, a gastro-entrological disease, a pulmonary disease, a cardiac disease, a manifestation of a therapeutic intervention, a manifestation of a pharmacological intervention, a side effect of a pharmacological intervention, a manifestation of substance abuse, a genetic disease, a nutritional disease, a malnutritional disease, an infectious disease, a disease related to the extracellular matrix, a disease related to connective tissues, a toxicological disease, and a condition related to toxic agents.

### Claim at position 24

-29. (canceled)

### Claim 30 (depends on 1)

The method of claim 1, wherein the microparticles are microspheres.

### Claim at position 26

-35. (canceled)

### Claim 36 (depends on 1)

The method of claim 1, wherein the microparticles are magnetic and/or paramagnetic.

### Claim 37 (depends on 1)

The method of claim 1, wherein the microparticles have a radiodensity greater than that of surrounding tissue.

### Claim 38 (depends on 1)

The method of claim 1, wherein the microparticles comprise and/or are filled with a therapeutic substance for targeted delivery.

### Claim 39 (depends on 1)

The method of claim 1, wherein the non-invasive detection device comprises one or more members selected from the group consisting of a mydriatic retinal camera, a non-mydriatic retinal camera, a magnetic resonance imaging device, an ultrasound device, a computed tomography scanner, and an optical coherence tomography device.

### Claim 40 (depends on 1)

The method of claim 1, wherein the non-invasive detection device detects one or more of the administered microparticles in vivo.

### Claim at position 32

-42. (canceled)

### Claim 43 (depends on 1)

The method of claim 1, wherein the blood vessel is an ocular blood vessel and wherein the non-invasive detection device detects one or more of the administered microparticles in the blood vessel without requiring cutting a cremaster muscle of the subject.

### Claim 44 (depends on 1)

The method of claim 1, comprising administering at least two populations of microparticles, wherein a first population is coated with a first substance and a second population is coated with a second, different substance.

### Claim 45 (depends on 44)

The method of claim 44, wherein the first and second populations have different emission and/or excitation wavelengths.

### Claim at position 36

-48. (canceled)

### Claim 49 (depends on 1)

The method of claim 1, wherein the non-invasive detection device captures a sequence of images over time to detect movement of one or more of the microparticles.

### Claim 50 (depends on 49)

The method of claim 49, comprising the step of determining a rolling velocity of one or more of the microparticles.

### Claim 51 (depends on 1)

The method of claim 1, wherein the one or more substances conjugated to the surface of the microparticles comprise one or more members selected from the group consisting of monoclonal antibodies, adhesion proteins, and peptides.

### Claim 52 (depends on 1)

The method of claim 1, wherein the one or more substances conjugated to the surface of the microparticles comprise one or more members selected from the group consisting of an endothelial antigen, a leukocyte antigen, a platelet antigen, a micro-particle antigen, a bacterial antigen, a viral antigen, a parasite antigen, and a cancer cell antigen.

### Claim 53 (depends on 1)

The method of claim 1, wherein the one or more substances conjugated to the surface of the microparticles comprise one or more proteins accumulating on the intraluminal surface.

### Claim at position 42

-58. (canceled)

### Claim 59 (depends on 1)

The method of claim 1, wherein the one or more substances conjugated to the surface of the microparticles comprise one or more members selected from the group consisting of a selectin, an integrin, an immunoglobulin, a cadherin, and a liproprotein.

### Claim 60 (depends on 1)

The method of claim 1, wherein the one or more substances conjugated to the surface of the microparticles comprise one or more members selected from the group consisting of a selectin, a selectin ligand, an integrin, an immunoglobulin, a glycoprotein, a cadherin, an endothelial junctional protein, an epithelial junctional protein, sLewisx, a complement, a complement control protein, a type II transmembrane glycoprotein, a mucin, a TNF superfamily member, a TNF receptor, a cytokine, a cytokine receptor, a growth factor, a growth factor receptor, a chemokine, a chemokine receptor, a G-protein coupled receptor, an ADAMs, a membrane-bound enzyme, a Toll-like receptors (TLR), a major histocompatibility complex family member, a lectin superfamily member, a Haemopoietin cytokine receptor superfamily member, a member of an insulin receptor family of tyrosine-protein kinases, an EGFR family member, and a Transferrin superfamily member.

### Claim 61 (depends on 1)

The method of claim 1, wherein the one or more substances conjugated to the surface of the microparticles comprise one or more members selected from the group consisting of CD18, Very Late Antigen-4 (VLA-4), and P-selectin Glycoprotein Ligand-1 (PSGL-1).

### Claim 62 (depends on 1)

The method of claim 1, comprising the step of identifying one or more retinal and/or choroidal endothelial antigens selected from the group consisting of P-selectin, Intercellular Adhesion Molecule-1 (ICAM-1), Vascular Cell Adhesion Molecule-1 (VCAM-1), P-selectin Glycoprotein Ligand-1 (PSGL-1), profilin, and desmoplakin, based at least in part on the one or more microparticles detected in step (b).

### Claim 63 (depends on 1)

The method of claim 1, comprising the step of identifying one or more leukocyte antigens selected from the group consisting of CD18 and Very Late Antigen-4 (VLA-4), based at least in part on the one or more microparticles detected in step (b).

### Claim 64 (depends on 1)

The method of claim 1, comprising the step of identifying one or more leukocyte antigens expressed by leukocytes that are firmly adhered to endothelium of diabetic retinal vessels, based at least in part on the one or more microparticles detected in step (b).

### Claim 65

(canceled)

### Claim 66 (depends on 1)

The method of claim 1, wherein the microparticles have an average diameter no greater than 7 μm.

### Claim 67

(canceled)

### Claim 68 (depends on 1)

The method of claim 1, wherein the microparticles have an average diameter no greater than 3 μm.

### Claim 69 (depends on 1)

The method of claim 1, wherein the microparticles have an average diameter no greater than 2 μm.

### Claim 70

(canceled)

### Claim 71 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim at position 56

-90. (canceled)

### Claim 91

A method for the delivery of one or more agents to a targeted intraluminal surface of a blood vessel, the method comprising:
(a) administering to a subject microparticles carrying one or more agents, wherein the microparticles have an average diameter less than a diameter of a blood vessel of the subject in which the microparticles travel, and wherein the microparticles have a surface to which one or more binding substances are conjugated, wherein the one or more binding substances bind to one or more ligands on a targeted intraluminal surface of the blood vessel, thereby immobilizing the microparticles on the targeted intraluminal surface; and
(b) affecting the release of the one or more agents from the microparticles onto the targeted intraluminal surface.

### Claim 92 (depends on 91)

The method of claim 91, wherein the administered microparticles carry the one or more agents in the interior of the microparticles.

### Claim 93 (depends on 91)

The method of claim 91, wherein the administered microparticles carry the one or more agents on the surface of the microparticles and/or about the microparticles.

### Claim 94 (depends on 91)

The method of claim 91, wherein step (b) comprises applying electromagnetic radiation to affect the release of the one or more agents onto the targeted intraluminal surface.

### Claim 95 (depends on 94)

The method of claim 94, wherein the electromagnetic radiation is applied non-invasively.

### Claim at position 62

-98. (canceled)

### Claim 99 (depends on 91)

The method of claim 91, wherein step (b) comprises administering a releasing agent to the subject, wherein the releasing agent affects the release of the one or more agents from the microparticles onto the targeted intraluminal surface.

### Claim 100 (depends on 91)

The method of claim 91, wherein step (b) comprises allowing sufficient time to pass such that the microparticles break down, thereby releasing the one or more agents from the microparticles onto the targeted intraluminal surface.

### Claim 101 (depends on 91)

The method of claim 91, wherein the one or more agents comprise one or more therapeutic agents.

### Claim 102 (depends on 101)

The method of claim 101, wherein the one or more therapeutic agents comprises one or more members selected from the group consisting of autonomic drugs, cardiovascular-renal drugs, drugs affecting inflammation, drugs that act in the central nervous system, drugs for treatment of blood disease, drugs for treatment of inflammation, drugs for treatment of gout, drugs acting on blood, drugs acting on blood-forming organs, endocrine drugs, chemotherapeutic drugs, perinatal drugs, pediatric drugs, geriatric drugs, dermatologic drugs, drugs for treatment of gastrointestinal disease, botanicals, nutritional supplements, and homeopathic drugs.

### Claim 103 (depends on 91)

The method of claim 91, wherein the one or more substances conjugated to the surface of the microparticles comprise one or more members selected from the group consisting of a selectin, an integrin, an immunoglobulin, a cadherin, and a lipoprotein.

### Claim 104

(canceled)

### Claim 105 (depends on 103)

The method of claim 103, wherein the one or more substances conjugated to the surface of the microparticles comprises αvβ3 integrin.

### Claim 106 (depends on 91)

The method of claim 91, wherein the method delivers the one or more agents to injured endothelium during one or more of the following: acute inflammation, chronic inflammation, uveitis, diabetic retinopathy, glaucoma, and macular degeneration.

### Claim 107 (depends on 91)

The method of claim 91, wherein the one or more ligands on the intraluminal surface comprise an endothelial surface antigen, a leukocyte surface antigen, or both.

### Claim 108

A method for the delivery of one or more agents to a targeted intraluminal surface of a blood vessel, the method comprising administering to a subject microparticles carrying one or more agents, wherein the microparticles have an average diameter less than a diameter of a blood vessel of the subject in which the microparticles travel, and wherein the microparticles have a surface to which one or more binding substances are conjugated, wherein the one or more binding substances bind to one or more ligands on a targeted intraluminal surface of the blood vessel, thereby immobilizing the microparticles on the targeted intraluminal surface.
